Drug Trial Radar · NCT00649480
Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jan 2007
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- Mylan Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to investigate the bioequivalence of Mylan balsalazide disodium 750 mg capsules to Salix Colazal® 750 mg capsules following a single, oral 2250 mg (3 x 750 mg) dose administration under fed conditions.
Conditions
- Healthy
Interventions
BALSALAZIDE DISODIUM CAPSULES, 750 MGDrug
3x750mg, single dose fed
COLAZAL® Capsules 750 mgDrug
3x750mg, single dose fed
Primary outcomes
What the sponsor says the trial is designed to measure.
- BioequivalenceTime frame: within 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRACS Institute Ltd. - Cetero Research
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.